Short Bowel Syndrome Market to cross US$ 3.66 Bn by 2031

Patients with Short Bowel Syndrome at High Risk of Contracting Coronavirus

Patients with gastrointestinal (GI) diseases may be at increased risk for more severe illness due to the ongoing COVID-19 outbreak. Potential risk factors in these patients include their chronic inflammatory disease, comorbidities, and the use of glucocorticoids. Healthcare, being an essential industry, has compelled manufacturers in the short bowel syndrome market to maintain robust supply chains for treatment options and medicines to reduce morbidity and mortality rates.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111798

The GI tract may be susceptible to coronavirus infection due to the widely expressed angiotensin-converting enzyme 2 (ACE2) receptors in the intestine. Hence, companies in the short bowel syndrome market are increasing the availability of products through online, hospital, and retail pharmacies to meet patient requirements and keep revenue streams flowing during the pandemic.

Autologous Tissue Engineering Helps Overcome Challenges of Organ Transplant

Today, treating short bowel syndrome (SBS) requires long-term parenteral nutrition or an organ transplant. Since the outcome with the former treatment is uncertain, the latter is linked to the shortage of organs. Thus, researchers with the EU-funded INTENS project are striving to develop a better solution. Companies in the short bowel syndrome market are taking cues from such researchers to develop strategy for autologous tissue engineering, which is known as the process of treating an individual using their own cells or tissues.

The autologous tissue engineering strategy holds promising potentials to overcome the shortage of organs and avoid the need of the risky practice of suppressing the patient’s immune response.

Intravenous, Magnesium Supplements Improve Patient Quality of Life

The short bowel syndrome market is estimated to cross US$ 3.66 Bn by 2031. Apart from glucagon-like peptide-2 (GLP2) and growth hormones, companies are boosting their production capabilities in fish oil-based emulsions for patients suffering from intestinal failure-associated liver disease and liver cholestasis.

There is a growing demand for intravenous supplementation of fluids to maintain normal hydration and urinary flow for patients suffering from SBS. Manufacturers in the short bowel syndrome market are increasing efforts to meet this demand, since SBS patients suffer from complications such as dehydration, hyponatremia, and chronic renal failure. Since hypomagnesemia is caused by malabsorption of magnesium due to loss of the distal ileum, manufacturers are producing magnesium supplements to help patients achieve adequate hydration.

Oral Rehydration Products, Prescription Medicines Create Stable Revenue Sources

Nutritional support, medications, and surgery are the most preferred treatment options for SBS. Companies in the short bowel syndrome market are expanding their revenue streams in oral rehydration products including sports drinks and sodas without caffeine. Children are being recommended special drinks that contain salts and minerals such as Infalyte, CeraLyte, and Pedialyte, which are being made available at drug stores and grocery stores, to prevent dehydration.

Manufacturers in the short bowel syndrome market are establishing stable income sources through prescription medicines such as antibiotics, H2 blockers, proton pump inhibitors, and the likes to improve patient outcomes.

Analysts’ Viewpoint

Since patients with COVID-19 have reported gastrointestinal symptoms, such findings are creating additional revenue opportunities for manufacturers in the short bowel syndrome market. The short bowel syndrome market is expected to grow at a CAGR of 15.9% during the forecast period. However, the SBS treatment requires long-term parenteral nutrition or an organ transplant. Hence, companies should collaborate with researchers to increase the study in autologous tissue engineering, which helps in treating an individual using their own cells or tissues. Companies are boosting their output capacities in anti-secretin agents to help patients reduce gastric acid in the intestine, growth hormones, and hypomotility agents to increase the time it takes the food to travel through intestines, resulting in increased nutrient absorption.

Short Bowel Syndrome Market: Overview

The global short bowel syndrome market for the historical years 2017 and 2018 and forecast period of 2021–2031, rise in prevalence of short bowel syndrome, increase in demand for SBS drugs due to high cost of parenteral nutrition, and favorable reimbursement policies are projected to drive the global short bowel syndrome market during the forecast period

According to the report, the global short bowel syndrome market was valued at US$ 728.3 Mn in 2020 and is anticipated to expand at a CAGR of 15.9% from 2021 to 2031

High Cost of Parenteral Nutrition Increases Demand for SBS Drugs: Key Driver

Most of the short bowel syndrome patients are on parenteral nutrition initially until the patients’ intestine has adopted and hemostasis is being maintained. The cost of parenteral nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per year. High cost of parenteral nutrition increases the demand for short bowel syndrome drugs, which have shown the ability to reduce patient’s dependence on parenteral nutrition during clinical trials.

For instance, apraglutide has the potential to enable patients to minimize the burden from parenteral support by increasing intestinal absorption of fluids, calories, and nutrients. Apraglutide has completed phase 2 studies and is currently being evaluated in a pivotal phase 3 clinical trial. Based on preclinical and clinical data to date, apraglutide has the potential to facilitate the treatment SBS-IF by establishing less frequent dosing and improving outcomes in a clinically meaningful fashion to address the needs of patients across the anatomical spectrum that characterizes the disease.

Rise in Prevalence of Short Bowel Syndrome to Boost Global Market

Prevalence of short bowel syndrome has risen across the globe in the past few years. This can be attributed to increase in the number of patients on total parenteral nutrition. The prevalence of short bowel syndrome is expected to be around four people per million, and the incidence is around three people per million.

The exact prevalence of the disease, however, is not clear, and it is estimated based on the number of people on parenteral nutrition. Rise in prevalence and incidence of the rare disease is likely to fuel the growth of the global market.

Approved drugs for the treatment of short bowel syndrome are not available globally and numerous other therapies are under clinical trials for the condition

High Cost of Treatment to Hamper Market

The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for low-income groups. Additionally, lack of reimbursement in certain countries renders the treatment unreachable to several target group people.

In May 2019, the U.S. Food and Drug Administration (FDA) approved extending the indication of Gattex (teduglutide) for injection to pediatric patients 1 year of age and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug used to treat adults with short bowel syndrome (SBS). Gattex is quite expensive, with treatment costing over US$ 295,000 a year.

The cost of treatment for the lifetime renders the treatment unaffordable, as rare diseases are life-threatening and do not have a permanent cure, thereby leading to a decline in the number of patients preferring to avail the treatment

Short Bowel Syndrome Market: Competition Landscape

This report profiles major players in the global short bowel syndrome market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Leading players operating in the global short bowel syndrome market are

• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Zealand Pharma A/S
• OxThera
• VectivBio AG
• 9 Meters Biopharma, Inc.
• Nutrinia Ltd.
• Hanmi Pharm.Co., Ltd.
• Pharmascience, Inc.

Key Questions Answered in Short Bowel Syndrome Market Report

• What is the scope of growth of companies present in the global short bowel syndrome market?
• What will be the Y-o-Y growth of the global short bowel syndrome market between 2021 and 2031?
• What is the influence of changing trends in technologies on the global short bowel syndrome market?
• Will North America continue to be the most profitable market for short bowel syndrome market?
• Which factors are anticipated to hamper the growth of the global short bowel syndrome market during the forecast period?
• Which are the key companies in the global short bowel syndrome market?

Short Bowel Syndrome Market – Segmentation

Product

• Glucagon-like Peptide-2 (GLP2)
• Growth Hormone
• Glutamine
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

Region

• North America
• Europe
• Japan
• Australia
• Rest of the World

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111798/2900